enzastaurin has been researched along with Cancer of Ovary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amant, F; Bauknecht, T; Casado, A; Chekerov, R; Emerich, J; Harter, P; Mansouri, K; Myrand, SP; Nguyen, TS; Sehouli, J; Shi, P; Vergote, IB | 1 |
| Vergote, I | 1 |
| Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I | 1 |
| Amant, F; Cadron, I; Drijkoningen, K; Leunen, K; Luyten, C; Mihalyi, A; Van Gorp, T; Vergote, I | 1 |
| Benbrook, DM; Darcy, KM; De Geest, K; Godwin, AK; Hanjani, P; Hurteau, JA; Mannel, RS; Michelin, DP; Sill, MW; Usha, L | 1 |
1 review(s) available for enzastaurin and Cancer of Ovary
| Article | Year |
|---|---|
Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Female; Humans; Indoles; Ovarian Neoplasms; Treatment Outcome | 2014 |
3 trial(s) available for enzastaurin and Cancer of Ovary
| Article | Year |
|---|---|
Randomized, phase II, placebo-controlled, double-blind study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment followed by maintenance treatment in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Ovarian Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta | 2013 |
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Class I Phosphatidylinositol 3-Kinases; Female; Genes, p53; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Vascular Endothelial Growth Factor A | 2011 |
1 other study(ies) available for enzastaurin and Cancer of Ovary
| Article | Year |
|---|---|
The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; CA-125 Antigen; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Indoles; Ovarian Neoplasms; Paclitaxel | 2010 |